Relmada Therapeutics (RLMD) Assets (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Assets data on file, last reported at $235.4 million in Q1 2026.

• Assets for Q1 2026 came in at $235.4 million, up 750.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $235.4 million (up 750.32% YoY), and the FY2025 annual result was $94.0 million, up 105.17% from the prior year.
• Assets improved to $235.4 million in Q1 2026 per RLMD's latest filing, from $94.0 million in the prior quarter.
• Over five years, Assets peaked at $235.4 million in Q1 2026 and troughed at $14.9 million in Q3 2025.
• A 5-year average of $111.5 million and a median of $97.6 million in 2023 frame the typical range for Assets.
• The sharpest annual moves came in 2025 and 2026: Assets plunged 73.3% in 2025, then soared 750.32% in 2026.
• A 5-year view of Assets shows it stood at $152.9 million in 2022, then slumped by 36.2% to $97.6 million in 2023, then tumbled by 53.03% to $45.8 million in 2024, then jumped by 105.17% to $94.0 million in 2025, then jumped by 150.38% to $235.4 million in 2026.
• Business Quant data shows RLMD's Assets at $235.4 million in Q1 2026, $94.0 million in Q4 2025, and $14.9 million in Q3 2025.